{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T16:54:07Z","timestamp":1770742447945,"version":"3.49.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T00:00:00Z","timestamp":1734998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009776","name":"McMaster University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009776","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Farmacia Hospitalaria"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.farma.2024.12.007","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T23:20:18Z","timestamp":1739488818000},"page":"T205-T211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["[Translated article] Pharmacokinetic-guided switching from standard half-life factor VIII to extended half-life pegylated factor VIII in haemophilia A therapy in clinical practice"],"prefix":"10.1016","volume":"49","author":[{"given":"Maria","family":"Chov\u00ed-Trull","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Eduardo","family":"Meg\u00edas-Vericat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Bonanad Boix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saturnino","family":"Haya Guaita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Rosa","family":"Cid Haro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Aguilar Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Luis","family":"Poveda Andr\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.farma.2024.12.007_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101164","article-title":"Nothing short of a revolution: novel extended half-life factor VIII replacement products and non-replacement agents reshape the treatment landscape in haemophilia A","volume":"64","author":"Abdelgawad","year":"2024","journal-title":"Blood Rev."},{"issue":"3","key":"10.1016\/j.farma.2024.12.007_bb0010","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jtha.2022.12.029","article-title":"Haemophilia treatment innovation: 50\u202fyears of progress and more to come","volume":"21","author":"Mannucci","year":"2023","journal-title":"J Thromb Haemost."},{"issue":"Suppl 6","key":"10.1016\/j.farma.2024.12.007_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of haemophilia, 3rd ed","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"issue":"10","key":"10.1016\/j.farma.2024.12.007_bb0020","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1080\/17474086.2019.1645002","article-title":"Pharmacokinetic and safety considerations when switching from standard to extended half-life clotting factor concentrates in haemophilia","volume":"12","author":"Morfini","year":"2019","journal-title":"Expert Rev Hematol."},{"issue":"4","key":"10.1016\/j.farma.2024.12.007_bb0025","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3390\/jcm6040039","article-title":"Outcome of clinical trials with new extended half-life FVIII\/IX concentrates","volume":"6","author":"Mancuso","year":"2017","journal-title":"J Clin Med."},{"issue":"7","key":"10.1016\/j.farma.2024.12.007_bb0030","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1111\/jth.14153","article-title":"Pharmacokinetics and the transition to extended half-life factor concentrates: communication from the SSC of the ISTH","volume":"16","author":"Ragni","year":"2018","journal-title":"J Thromb Haemost."},{"issue":"3","key":"10.1016\/j.farma.2024.12.007_bb0035","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/hae.13977","article-title":"Development and evaluation of the population pharmacokinetic models for FVIII and FIX concentrates of the WAPPS-Hemo project","volume":"26","author":"Hajducek","year":"2020","journal-title":"Haemophilia"},{"issue":"2","key":"10.1016\/j.farma.2024.12.007_bb0040","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/rth2.12476","article-title":"Extended half-life factor VIII concentrates in adults with haemophilia A: comparative pharmacokinetics of two products","volume":"5","author":"Teitel","year":"2021","journal-title":"Res Pract Thromb Haemost."},{"issue":"2","key":"10.1016\/j.farma.2024.12.007_bb0045","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/hae.14960","volume":"30","author":"Matino","year":"2024","journal-title":"Haemophilia"},{"issue":"3","key":"10.1016\/j.farma.2024.12.007_bb0050","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1111\/hae.13403","article-title":"Real-world experience with use of antihemophilic factor (recombinant), PEGylated for prophylaxis in severe haemophilia A","volume":"24","author":"Dunn","year":"2018","journal-title":"Haemophilia"},{"issue":"6","key":"10.1016\/j.farma.2024.12.007_bb0055","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1111\/hae.14649","article-title":"Switching from standard to extended half-life FVIII prophylaxis in haemophilia A: comparison of factor product use, bleed rates and pharmacokinetics","volume":"28","author":"Nummi","year":"2022","journal-title":"Haemophilia"},{"issue":"4","key":"10.1016\/j.farma.2024.12.007_bb0060","first-page":"492","article-title":"A Retrospective observational study of rurioctocog alfa pegol in clinical practice in the United States","volume":"26","author":"Aledort","year":"2020","journal-title":"J Manag Care Spec Pharm."},{"key":"10.1016\/j.farma.2024.12.007_bb0065","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.thromres.2022.06.001","article-title":"Pharmacokinetic and clinical improvements after PK-guided switch from standard half-life to extended half-life factor VIII products","volume":"216","author":"Meg\u00edas-Vericat","year":"2022","journal-title":"Thromb Res."},{"issue":"3","key":"10.1016\/j.farma.2024.12.007_bb0070","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/hae.13953","article-title":"Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: final results from the ASPIRE extension study","volume":"26","author":"Nolan","year":"2020","journal-title":"Haemophilia"},{"issue":"8","key":"10.1016\/j.farma.2024.12.007_bb0075","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1055\/a-1333-5536","article-title":"Decreased bleeding rates in patients with haemophilia A switching from standard-half-life FVIII to BAY 94\u20139027 prophylaxis","volume":"121","author":"Mancuso","year":"2021","journal-title":"Thromb Haemost."},{"issue":"9","key":"10.1016\/j.farma.2024.12.007_bb0080","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood-2015-03-630897","article-title":"Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe haemophilia A","volume":"126","author":"Konkle","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.farma.2024.12.007_bb0085","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/hae.14930","article-title":"Safety and efficacy of damoctocog alfa pegol prophylaxis in patients with severe haemophilia A: results of an interventional, post-marketing study","volume":"30","author":"Holme","year":"2024","journal-title":"Haemophilia"},{"issue":"02","key":"10.1016\/j.farma.2024.12.007_bb0090","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1160\/TH16-06-0444","article-title":"Clinical evaluation of glycoPEGylated recombinant FVIII: efficacy and safety in severe haemophilia A","volume":"117","author":"Giangrande","year":"2017","journal-title":"Thromb Haemost."},{"issue":"3","key":"10.1016\/j.farma.2024.12.007_bb0095","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/hae.13438","article-title":"Defining extended half-life rFVIII-A critical review of the evidence","volume":"24","author":"Mahlangu","year":"2018","journal-title":"Haemophilia"},{"issue":"4","key":"10.1016\/j.farma.2024.12.007_bb0100","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/jth.12161","article-title":"Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with haemophilia A","volume":"11","author":"Tiede","year":"2013","journal-title":"J Thromb Haemost."},{"issue":"3","key":"10.1016\/j.farma.2024.12.007_bb0105","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/hae.13712","article-title":"Once-weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8-GP) in severe haemophilia A: safety and efficacy results from pathfinder 2 (randomised phase III trial)","volume":"25","author":"Curry","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.farma.2024.12.007_bb0110","author":"ClinicalTrials.gov registration number: NCT01580293"},{"key":"10.1016\/j.farma.2024.12.007_bb0115","author":"ClinicalTrials.gov registration number: NCT01736475"},{"key":"10.1016\/j.farma.2024.12.007_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103678","article-title":"Clinical studies of extended-half-life recombinant FVIII products for prophylaxis in adults and children: a critical review from the physician's perspective","volume":"174","author":"Hermans","year":"2022","journal-title":"Crit Rev Oncol Hematol."},{"issue":"11","key":"10.1016\/j.farma.2024.12.007_bb0125","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1007\/s00277-020-04280-3","article-title":"Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomised, crossover pharmacokinetic study in patients with severe haemophilia A","volume":"99","author":"Solms","year":"2020","journal-title":"Ann Hematol."},{"issue":"1","key":"10.1016\/j.farma.2024.12.007_bb0130","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/medicina60010034","article-title":"Personalised prophylaxis with myPKFiTCE: a real-world cost-effectiveness analysis in haemophilia A patients","volume":"60","author":"Antonazzo","year":"2023","journal-title":"Medicina (Kaunas)"}],"container-title":["Farmacia Hospitalaria"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634324002046?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634324002046?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T23:48:56Z","timestamp":1770680936000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130634324002046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1130634324002046"],"URL":"https:\/\/doi.org\/10.1016\/j.farma.2024.12.007","relation":{},"ISSN":["1130-6343"],"issn-type":[{"value":"1130-6343","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"[Translated article] Pharmacokinetic-guided switching from standard half-life factor VIII to extended half-life pegylated factor VIII in haemophilia A therapy in clinical practice","name":"articletitle","label":"Article Title"},{"value":"Farmacia Hospitalaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2024.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2024.10.005","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Sociedad Espa\u00f1ola de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}